Hemophilia firm from former Novo employee secures millions from Novo Seeds

Following 12 years at Novo Nordisk, Johan Faber broke out last year to found the biotech firm Hemab, which will develop drugs against rare haemophilia diseases. The firm has just landed a two-digit million kroner investment from Novo Seeds.

Hemab CEO and Co-founder Johan Faber | Photo: Hemab / PR

A pile of money has been laid on the table belonging to the newly-founded biotech company Hemab, which develops pharmaceutical drugs against rare bleeding disorders for a market which is estimated to bring in billions of kroner.

Novo Seed has posted a million kroner figure in the double digits into Hemab, whose offices are located at the Copenhagen-based life science facility Cobis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs